Healthcare News | BioTuesdays by Kilmer Lucas IR

Developments

Ocugen to discontinue Phase 3 oGVHD trial

Ocugen (NASDAQ:OCGN) is discontinuing the Phase 3 trial of OCU300 for ocular graft vs. host disease (oGVHD) based on results of a pre-planned interim sample size analysis conducted by an independent data monitoring...

June 1, 2020

Markets

HCW starts Allena Pharma at buy; PT $10

H.C. Wainwright launched coverage of Allena Pharmaceuticals (NASDAQ:ALNA) with a “buy” rating and $10 price target. The stock closed at $1.68 on May 29. Allena is developing reloxaliase, an orally administered enzyme...

June 1, 2020

Developments

Menlo Therapeutics ZILXI gets FDA approval for rosacea

Menlo Therapeutics’ (NASDAQ:MNLO) ZILXI received FDA approval for the treatment of inflammatory lesions of rosacea in adults. The company noted that ZILXI, a minocycline topical foam, is the first minocycline product of...

May 29, 2020

Developments

Myovant Sciences updates positive data from Phase 3 prostate cancer trial

Myovant Sciences’ (NASDAQ:MYOV) reported additional positive results from its Phase 3 HERO study of once-daily, oral relugolix in men with advanced prostate cancer. In the primary endpoint responder analysis, 97% of men...

May 29, 2020

Developments

AVEO Oncology reports positive overall survival results from Phase 3 RCC study

AVEO Oncology (NASDAQ:AVEO) reported positive final overall survival results from its Phase 3 TIVO-3 trial comparing tivozanib to sorafenib in third- and fourth-line renal cell carcinoma (RCC). The trial met the...

May 29, 2020

Markets

BTIG starts Fulgent Genetics at buy; PT $20

BTIG initiated coverage of Fulgent Genetics (NASDAQ:FLGT) with a “buy” rating and $20 price target. The stock closed at $16.06 on May 28. Fulgent is a genetic testing service provider that has delivered more than...

May 29, 2020

Developments

Repare Therapeutics in research collaboration with Bristol Myers

Closely-held Repare Therapeutics inked an exclusive, worldwide research collaboration with Bristol Myers Squibb (NYSE:BMY). Under the accord, the companies will leverage Repare’s CRISPR-enabled genome-wide synthetic...

May 28, 2020

Developments

Cardiff Oncology onvansertib gets FDA fast track designation for colorectal cancer

Cardiff Oncology’s (NASDAQ:CRDF) onvansertib received FDA fast track designation for the second-line treatment of patients with KRAS-mutated metastatic colorectal cancer (mCRC). The company is currently assessing...

May 28, 2020

Markets

Analysts up Mersana Therapeutics PT to $21

Analysts for SVB Leerink and BTIG raised their price targets for Mersana Therapeutics (NASDAQ:MRSN) to $21 from $12 and $14, respectively, citing positive interim data from the expansion portion of the company’s Phase 1...

May 27, 2020

Developments

Zynerba Pharmaceuticals reports positive topline results from Phase 2 trial of Zygel in ASD

Zynerba Pharmaceuticals (NASDAQ:ZYNE) reported positive topline data from its Phase 2 trial of Zygel for the treatment of autism spectrum disorder (ASD). Zygel is a cannabidiol-based gel that provides controlled...

May 27, 2020

Markets

Brookline starts CohBar at buy; PT $10

Brookline Capital Markets initiated coverage of CohBar (NASDAQ:CWBR) with a “buy” rating and $10 price target. The stock closed at $2.63 on May 26. CohBar is developing CB4211, a novel and optimized analog of MOTS-c, a...

May 27, 2020

Developments

IntelGenx schedules meeting with the FDA to discuss RIZAPORT NDA

The FDA has granted IntelGenx Technologies’ (TSXV:IGX; OTCQX:IGXT) request for a Type A meeting to discuss the company’s RIZAPORT VersaFilm program. The meeting is scheduled for June 10, 2020. On March...

May 27, 2020

Ocugen to discontinue Phase 3 oGVHD trial

HCW starts Allena Pharma at buy; PT $10

Menlo Therapeutics ZILXI gets FDA approval for rosacea

Myovant Sciences updates positive data from Phase 3 prostate cancer trial

AVEO Oncology reports positive overall survival results from Phase 3 RCC study

BTIG starts Fulgent Genetics at buy; PT $20

Repare Therapeutics in research collaboration with Bristol Myers

Cardiff Oncology onvansertib gets FDA fast track designation for colorectal cancer

Analysts up Mersana Therapeutics PT to $21

Zynerba Pharmaceuticals reports positive topline results from Phase 2 trial of Zygel in ASD

Brookline starts CohBar at buy; PT $10

IntelGenx schedules meeting with the FDA to discuss RIZAPORT NDA

Follow Us

General

More

Sign up for the BioTuesdays weekly newsletter